This is the last of the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®. Our multidisciplinary panel will discuss the challenges with patient monitoring while on Trastuzumab Deruxtecan ENHERTU®. When to dose adjust and hold or even discontinue Trastuzumab Deruxtecan ENHERTU®. Once again, the podcast ends with take home points for patient monitoring and side effects while on Trastuzumab Deruxtecan ENHERTU®.  

2023-2024 SGO Chemotherapy and Targeted Therapies Subcommittee Member and Moderator:
Tracilyn Hall, MD

Speakers:
Jennifer MacDonald, PharmD, BCOP
Kathleen Moore, MD
Bernard Tawfik, MD 

In honor of Endometrial Cancer Awareness Month, we encourage you to read the latest HER2 Molecular Card and Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card available now on SGO ConnectEd.

HER2 Molecular Card: https://connected.sgo.org/content/molecular-target-human-epidermal-growth-factor-receptor-2-her2

Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card: https://connected.sgo.org/content/chemotherapy-targeted-therapies-flash-cards

This is the second of the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®.  Our multidisciplinary panel will discuss the important information about the drug preparation and administration of Trastuzumab Deruxtecan ENHERTU®.  Focusing on dosing, breast scoring, HER2, infusion reactions, lab examinations, and patient education. The session ends with general take home points on administration and toxicity prevention interventions.

2023-2024 SGO Chemotherapy and Targeted Therapies Subcommittee Member and Moderator:
Tracilyn Hall, MD

Speakers:
Jennifer MacDonald, PharmD, BCOP
Kathleen Moore, MD
Bernard Tawfik, MD 

In honor of Endometrial Cancer Awareness Month, we encourage you to read the latest HER2 Molecular Card and Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card available now on SGO ConnectEd.

HER2 Molecular Card: https://connected.sgo.org/content/molecular-target-human-epidermal-growth-factor-receptor-2-her2

Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card: https://connected.sgo.org/content/chemotherapy-targeted-therapies-flash-cards

This is the first of the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®. After going over some general information on Trastuzumab Deruxtecan ENHERTU® including when to use the drug, checking patient performance status, toxicity, response rates in breast, and line of therapy and treatment option. The multidisciplinary panel will discuss dosing and drug preparation for giving Trastuzumab Deruxtecan ENHERTU®. The session wraps up with some key take home points on Trastuzumab Deruxtecan ENHERTU®. 

2023-2024 SGO Chemotherapy and Targeted Therapies Subcommittee Member and Moderator:
Tracilyn Hall, MD

Speakers:
Jennifer MacDonald, PharmD, BCOP
Kathleen Moore, MD
Bernard Tawfik, MD 

In honor of Endometrial Cancer Awareness Month, we encourage you to read the latest HER2 Molecular Card and Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card available now on SGO ConnectEd.

HER2 Molecular Card: https://connected.sgo.org/content/molecular-target-human-epidermal-growth-factor-receptor-2-her2

Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card: https://connected.sgo.org/content/chemotherapy-targeted-therapies-flash-cards

In this podcast, we will focus on same day discharge as part of Enhanced Recovery after Surgery (ERAS).

Over the past two decades, and especially after the publication of the GOG LAP2 trial, minimally invasive surgery has been widely adopted in gynecologic oncology, as it is associated with lower rates of complications, and improved postoperative recovery and return to normal activity. 

Postoperative hospitalization is typically shorter after minimally invasive (MIS) hysterectomy, and many patients may even be candidates for discharge on the day of surgery, so-called same-day discharge (SDD).

2023-2024 SGO ERAS Subcommittee Members and Speakers:
Lee-may Chen, MD; Subcommittee Lead and Moderator
Nawar Latif, MD, MPH, MSCE
Clarissa Polen-De, MD
Michael Shu, MD
Collin Sitler, DO
Brenna Swift, MD, MASc, MSc, FRCSC
Diogo Torres, MD

This episode is part 3 of the Immunotherapy podcast series, which continues discussion of common controversies affecting the use of immune checkpoint inhibitors (ICIs) in the clinic, such as optimal dosing strategies, influence of toxicity on response and survival, and sequencing.

Moderator:
Karin K. Shih, MD
Gynecologic Oncologist & Assistant Professor - Zucker School of Medicine at Hofstra/Northwell

Speakers:
Erin Zacholski, PharmD, BCOP
Assistant Professor - VCU School of Pharmacy
Clinical Pharmacy Specialist, Gynecologic Oncology -  VCU Health Massey Cancer Center

Sarah Hayward, PharmD, BCOP
Clinical Pharmacy Specialist, Gynecologic Oncology - OU Health Stephenson Cancer Center

This episode is part 2 of the Immunotherapy Series, which reviews common controversies affecting daily use of immune checkpoint inhibitors (ICIs) in the clinic, such as treatment options for immune related adverse effects beyond corticosteroids, re-challenging after toxicity, use of ICIs in patients with auto-immune conditions, and drug interactions.

Moderator:
Karin K. Shih, MD
Gynecologic Oncologist & Assistant Professor - Zucker School of Medicine at Hofstra/Northwell

Speakers:
Erin Zacholski, PharmD, BCOP
Assistant Professor - VCU School of Pharmacy
Clinical Pharmacy Specialist, Gynecologic Oncology -  VCU Health Massey Cancer Center

Sarah Hayward, PharmD, BCOP
Clinical Pharmacy Specialist, Gynecologic Oncology - OU Health Stephenson Cancer Center

Join Dr. Robert Neff as he interviews Drs. Kathleen Moore and Charles Leath, III to discuss the latest NRG Oncology updates on upcoming studies, research, and trials. The focus for the podcast is to bridge the gaps between SGO members and NRG Oncology.  

 Some questions covered during the interview:

1.  Since NRG just celebrated its 10-year anniversary during the Summer Meeting, what is the vision for NRG in the next 10 years?
2. What are some of the successes within the past year for the Ovary Subcommittee?
3. What were the most important highlights from the Cervix and Vulvar Subcommittee?
4. Are there opportunities for new members to be involved? 

This episode was created by Dr. Robert Neff, 2023-2024 member of the SGO Education Committee's Clinical Trials Management/Concepts Subcommittee. Thanks to Drs. Moore and Leath, III for your contribution to this episode.

Moderator:
Robert Neff, MD

Speakers:
Kathleen Moore, MD
Charles Leath, III, MD 

Episode three of the Radiation Therapy podcast series discusses radiation techniques and management with regard to locally advanced cervical cancer. 

Host/Moderator:
Leigh A. Cantrell, MD, MSPH
Professor, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology - University of Virginia

Guest Speaker:
Kara Romano, M.D.
Assistant Professor, Department of Radiation Oncology - University of Virginia

Join Dr. Janelle Darby, member of the SGO Clinical Trials Management/Concepts Subcommittee, as she interviews Drs. Evan Graboyes, Jeffrey Hines, and Bhavana Pothuri, addressing continued efforts to improve inclusion of racially and ethnically diverse patients in clinical trials.   

Some topics covered during the interview:

1. Barriers to clinical trial enrollment and retention among racially and ethnically diverse patient populations.
2. Role of cooperative research groups in improving access to clinical trials for racially and ethnically diverse patient populations. 
3. Discussion of resources and strategies to improve recruitment and retention of racially and ethnically diverse patient populations in clinical trials.

2023-2024 SGO  Clinical Trials Management/Concepts Subcommittee Member and Moderator:
Janelle Pakish Darby, MD

Speakers:
Evan Graboyes, MD, MPH, FACS
Jeffrey Hines, MD
Bhavana Pothuri, MD, MS

This podcast focuses on the surgical site infection reduction bundle as part of the ERAS guidelines that was first published in 2016 and updated in 2019, and the 2020 vulvar and vaginal surgeries ERAS guidelines.

Before we dive into the SSI reduction bundle, we want to highlight the importance of patient education and participation in any ERAS protocol. Pre-operative education and psychological preparation is critical. Written information was determined to be superior to verbal in a randomized clinical trial in gynecologic oncology surgery.

2023-2024 SGO ERAS Subcommittee Members and Speakers:
Lee-may Chen, MD; Subcommittee Lead and Moderator
Nawar Latif, MD, MPH, MSCE
Collin Sitler, DO
Brenna Swift, MD, MASc, MSc, FRCSC